Retrophin Inc. Cmn (RTRX) 18.17 $RTRX
Gilead's (GILD) HIV Treatment Odefsey Gains Approval in EU
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 9:08AM CDT
Gilead Sciences' (GILD) once-daily single tablet regimen Odefsey gained EU approval for the treatment of HIV-1 infection in certain patients.
JNJ: 125.40 (+0.17), GILD: 80.46 (+0.99), ANIP: 61.06 (+0.46), RTRX: 18.17 (+0.24)
Retrophin (RTRX) RE-024 Positive in Physician-Initiated Study
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 5:54AM CDT
Retrophin (RTRX) announced new data from a physician-initiated study on RE-024 for the treatment of pantothenate kinase-associated neurodegeneration (PKAN).
ANIP: 61.06 (+0.46), PFE: 37.31 (+0.42), RTRX: 18.17 (+0.24), ORPN: 1.62 (-0.10)
Anavex's Lead Candidate Gets Orphan Drug Status Yet Again
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 5:22PM CDT
Anavex Life Sciences (AVXL) announced that ANAVEX 2-73 has been granted orphan drug status by the FDA for the treatment of infantile spasms.
AVXL: 3.61 (-0.23), ANIP: 61.06 (+0.46), RTRX: 18.17 (+0.24), ACOR: 25.13 (-0.15)
Nymox (NYMX) Stock Up on Positive 7-Year Fexapotide Data
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 7:51AM CDT
Nymox (NYMX) announced positive results from the seven-year, prospective, placebo-controlled, double-blind study on fexapotide (NX-1207).
ANIP: 61.06 (+0.46), PFE: 37.31 (+0.42), RTRX: 18.17 (+0.24), NYMX: 3.35 (-0.25)
Retrophin Announces New Data from Physician-Initiated Treatment with RE-024 at the 20th International Congress of Parkinson's Disease and Movement Disorders
GlobeNewswire - Thu Jun 23, 5:00AM CDT
Retrophin, Inc. (NASDAQ:RTRX) today announced new data from physician-initiated treatment with RE-024, the company's novel investigational replacement therapy for pantothenate kinase-associated neurodegeneration (PKAN), a rare and life-threatening genetic condition characterized by a host of progressively debilitating movement disorders. Key findings suggest RE-024 was safe and well tolerated in two adults with PKAN who experienced clinically meaningful improvements, followed by stabilization of disease progression over 47 weeks of treatment.
RTRX: 18.17 (+0.24)
Prima Reports Favorable Initial Breast Cancer Study Data
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 2:30PM CDT
Prima BioMed Ltd (PBMD) announced initial data from a phase IIb chemo-immunotherapy study on IMP321 for the treatment of metastatic breast cancer.
PBMD: 0.90 (-0.03), ANIP: 61.06 (+0.46), RTRX: 18.17 (+0.24), CELG: 114.69 (+2.50)
GW Pharma (GWPH) to Develop Epidiolex for Infantile Spasms
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 9:53AM CDT
GW Pharmaceuticals (GWPH) has selected infantile spasms as the fourth target indication for the development of Epidiolex.
GWPH: 96.11 (+1.79), ANIP: 61.06 (+0.46), RTRX: 18.17 (+0.24), BMY: 76.19 (+1.38)
Inovio Stock Up, Zika Vaccine Gets Nod for Phase I Study
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 3:51PM CDT
Inovio Pharmaceuticals (INO) and GeneOne Life Science will begin the first Zika vaccine study in human volunteers; Inovio's stock gains.
INO: 10.42 (+0.54), ANIP: 61.06 (+0.46), XON: 27.38 (+2.05), RTRX: 18.17 (+0.24)
Fate's (FATE) ProTmune Gets Fast Track Status, Stock Up
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 10:46AM CDT
Fate Therapeutics (FATE) announced that the FDA has granted the Fast Track status to its immunotherapy ProTmune.
FATE: 1.99 (-0.08), ANIP: 61.06 (+0.46), RTRX: 18.17 (+0.24), ACOR: 25.13 (-0.15)
Gilead Presents Favorable Preliminary Bictegravir HIV Data
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 10:21AM CDT
Gilead Sciences (GILD) presented encouraging preliminary data from four pre-clinical and phase I studies evaluating bictegravir for the treatment of HIV.
GILD: 80.46 (+0.99), ANIP: 61.06 (+0.46), RTRX: 18.17 (+0.24), BMY: 76.19 (+1.38)
Auris (EARS) Begins Phase III Study for Sudden Deafness
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 9:31AM CDT
Auris Medical (EARS) has started patient enrollment in a second pivotal phase III study (ASSENT) on AM-111 for the treatment of sudden deafness.
EARS: 4.14 (+0.13), ANIP: 61.06 (+0.46), RTRX: 18.17 (+0.24), BMY: 76.19 (+1.38)
Kura (KURA) Begins Dosing in Phase II Study on Cancer Drug
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 3:18PM CDT
Kura Oncology (KURA) announced the dosing of the first patient in a phase II study on tipifarnib for the treatment of lower risk myelodysplastic syndromes.
JNJ: 125.40 (+0.17), RTRX: 18.17 (+0.24), KURA: 4.31 (+0.20), BMY: 76.19 (+1.38)
7 Biotech Stocks that are Buys Right Now
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 10:00AM CDT
Buy these seven biotech stocks now and see how well the second half of 2016 unfolds for this industry.
MSTX: 0.36 (unch), RTRX: 18.17 (+0.24), AVEO: 0.99 (-0.01), SNSS: 0.70 (+0.05), LGND: 138.53 (+3.65), BIND: 0.78 (-0.09), ACOR: 25.13 (-0.15)
Zacks.com featured highlights: Dycom Industries, QVC Group, Retrophin, Facebook and Gener8 Maritime
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 8:30AM CDT
Zacks.com featured highlights: Dycom Industries, QVC Group, Retrophin, Facebook and Gener8 Maritime
GNRT: 5.11 (-0.21), FB: 124.31 (+0.37), RTRX: 18.17 (+0.24), QVCA: 26.55 (-0.26), DY: 93.78 (-0.27)
5 Profitable Stocks for Enhancing Your Portfolio Returns
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 7:18AM CDT
Among the profitability ratios, we have used net income ratio to determine a company's profitability position.
GNRT: 5.11 (-0.21), FB: 124.31 (+0.37), RTRX: 18.17 (+0.24), QVCA: 26.55 (-0.26), DY: 93.78 (-0.27)
Revance's Lead Candidate Fails in Phase III Crow's Feet Study
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 10:28AM CDT
Revance Therapeutics' (RVNC) RT001 topical failed to meet the co-primary and other endpoints in a phase III crow's feet study.
PFE: 37.31 (+0.42), RTRX: 18.17 (+0.24), RVNC: 13.25 (-0.24), BMY: 76.19 (+1.38)
Agios Reports Favorable Phase II PK Deficiency Study Data
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 8:56AM CDT
Agios Pharmaceuticals (AGIO) reported encouraging initial data from an ongoing phase II DRIVE-PK study on pyruvate kinase deficiency candidate AG-348.
PFE: 37.31 (+0.42), RTRX: 18.17 (+0.24), AGIO: 45.69 (+0.46), BMY: 76.19 (+1.38)
Glaxo/J&J Sirukumab Positive in Rheumatoid Arthritis Study
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 10:01AM CDT
GlaxoSmithKline (GSK) and Johnson & Johnson's Janssen Biologics announced encouraging new phase III study data on rheumatoid arthritis candidate, sirukumab.
JNJ: 125.40 (+0.17), RTRX: 18.17 (+0.24), GSK: 45.25 (+0.18), BMY: 76.19 (+1.38)
The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
MACK: 5.82 (+0.02), BIIB: 301.83 (+11.90), IDRA: 1.67 (-0.05), RTRX: 18.17 (+0.24), ACOR: 25.13 (-0.15)
Orexigen Stock Gains More than 50% on Markman Hearing
Arpita Dutt - Zacks Investment Research - Thu Jun 09, 7:58AM CDT
Orexigen's (OREX) shares shot up on a favorable Markman hearing in the Contrave patent infringement lawsuit.
OREX: 3.38 (+0.03), RTRX: 18.17 (+0.24), VVUS: 1.05 (-0.02), ARNA: 1.68 (+0.01)
Gilead's (GILD) HIV Treatment Odefsey Gains Approval in EU
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 9:08AM CDT
Gilead Sciences' (GILD) once-daily single tablet regimen Odefsey gained EU approval for the treatment of HIV-1 infection in certain patients.
JNJ: 125.40 (+0.17), GILD: 80.46 (+0.99), ANIP: 61.06 (+0.46), RTRX: 18.17 (+0.24)
Retrophin (RTRX) RE-024 Positive in Physician-Initiated Study
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 5:54AM CDT
Retrophin (RTRX) announced new data from a physician-initiated study on RE-024 for the treatment of pantothenate kinase-associated neurodegeneration (PKAN).
ANIP: 61.06 (+0.46), PFE: 37.31 (+0.42), RTRX: 18.17 (+0.24), ORPN: 1.62 (-0.10)
Anavex's Lead Candidate Gets Orphan Drug Status Yet Again
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 5:22PM CDT
Anavex Life Sciences (AVXL) announced that ANAVEX 2-73 has been granted orphan drug status by the FDA for the treatment of infantile spasms.
AVXL: 3.61 (-0.23), ANIP: 61.06 (+0.46), RTRX: 18.17 (+0.24), ACOR: 25.13 (-0.15)
Nymox (NYMX) Stock Up on Positive 7-Year Fexapotide Data
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 7:51AM CDT
Nymox (NYMX) announced positive results from the seven-year, prospective, placebo-controlled, double-blind study on fexapotide (NX-1207).
ANIP: 61.06 (+0.46), PFE: 37.31 (+0.42), RTRX: 18.17 (+0.24), NYMX: 3.35 (-0.25)
Retrophin Announces New Data from Physician-Initiated Treatment with RE-024 at the 20th International Congress of Parkinson's Disease and Movement Disorders
GlobeNewswire - Thu Jun 23, 5:00AM CDT
Retrophin, Inc. (NASDAQ:RTRX) today announced new data from physician-initiated treatment with RE-024, the company's novel investigational replacement therapy for pantothenate kinase-associated neurodegeneration (PKAN), a rare and life-threatening genetic condition characterized by a host of progressively debilitating movement disorders. Key findings suggest RE-024 was safe and well tolerated in two adults with PKAN who experienced clinically meaningful improvements, followed by stabilization of disease progression over 47 weeks of treatment.
RTRX: 18.17 (+0.24)
Prima Reports Favorable Initial Breast Cancer Study Data
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 2:30PM CDT
Prima BioMed Ltd (PBMD) announced initial data from a phase IIb chemo-immunotherapy study on IMP321 for the treatment of metastatic breast cancer.
PBMD: 0.90 (-0.03), ANIP: 61.06 (+0.46), RTRX: 18.17 (+0.24), CELG: 114.69 (+2.50)
GW Pharma (GWPH) to Develop Epidiolex for Infantile Spasms
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 9:53AM CDT
GW Pharmaceuticals (GWPH) has selected infantile spasms as the fourth target indication for the development of Epidiolex.
GWPH: 96.11 (+1.79), ANIP: 61.06 (+0.46), RTRX: 18.17 (+0.24), BMY: 76.19 (+1.38)
Inovio Stock Up, Zika Vaccine Gets Nod for Phase I Study
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 3:51PM CDT
Inovio Pharmaceuticals (INO) and GeneOne Life Science will begin the first Zika vaccine study in human volunteers; Inovio's stock gains.
INO: 10.42 (+0.54), ANIP: 61.06 (+0.46), XON: 27.38 (+2.05), RTRX: 18.17 (+0.24)
Fate's (FATE) ProTmune Gets Fast Track Status, Stock Up
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 10:46AM CDT
Fate Therapeutics (FATE) announced that the FDA has granted the Fast Track status to its immunotherapy ProTmune.
FATE: 1.99 (-0.08), ANIP: 61.06 (+0.46), RTRX: 18.17 (+0.24), ACOR: 25.13 (-0.15)
Gilead Presents Favorable Preliminary Bictegravir HIV Data
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 10:21AM CDT
Gilead Sciences (GILD) presented encouraging preliminary data from four pre-clinical and phase I studies evaluating bictegravir for the treatment of HIV.
GILD: 80.46 (+0.99), ANIP: 61.06 (+0.46), RTRX: 18.17 (+0.24), BMY: 76.19 (+1.38)
Auris (EARS) Begins Phase III Study for Sudden Deafness
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 9:31AM CDT
Auris Medical (EARS) has started patient enrollment in a second pivotal phase III study (ASSENT) on AM-111 for the treatment of sudden deafness.
EARS: 4.14 (+0.13), ANIP: 61.06 (+0.46), RTRX: 18.17 (+0.24), BMY: 76.19 (+1.38)
Kura (KURA) Begins Dosing in Phase II Study on Cancer Drug
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 3:18PM CDT
Kura Oncology (KURA) announced the dosing of the first patient in a phase II study on tipifarnib for the treatment of lower risk myelodysplastic syndromes.
JNJ: 125.40 (+0.17), RTRX: 18.17 (+0.24), KURA: 4.31 (+0.20), BMY: 76.19 (+1.38)
7 Biotech Stocks that are Buys Right Now
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 10:00AM CDT
Buy these seven biotech stocks now and see how well the second half of 2016 unfolds for this industry.
MSTX: 0.36 (unch), RTRX: 18.17 (+0.24), AVEO: 0.99 (-0.01), SNSS: 0.70 (+0.05), LGND: 138.53 (+3.65), BIND: 0.78 (-0.09), ACOR: 25.13 (-0.15)
Zacks.com featured highlights: Dycom Industries, QVC Group, Retrophin, Facebook and Gener8 Maritime
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 8:30AM CDT
Zacks.com featured highlights: Dycom Industries, QVC Group, Retrophin, Facebook and Gener8 Maritime
GNRT: 5.11 (-0.21), FB: 124.31 (+0.37), RTRX: 18.17 (+0.24), QVCA: 26.55 (-0.26), DY: 93.78 (-0.27)
5 Profitable Stocks for Enhancing Your Portfolio Returns
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 7:18AM CDT
Among the profitability ratios, we have used net income ratio to determine a company's profitability position.
GNRT: 5.11 (-0.21), FB: 124.31 (+0.37), RTRX: 18.17 (+0.24), QVCA: 26.55 (-0.26), DY: 93.78 (-0.27)
Revance's Lead Candidate Fails in Phase III Crow's Feet Study
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 10:28AM CDT
Revance Therapeutics' (RVNC) RT001 topical failed to meet the co-primary and other endpoints in a phase III crow's feet study.
PFE: 37.31 (+0.42), RTRX: 18.17 (+0.24), RVNC: 13.25 (-0.24), BMY: 76.19 (+1.38)
Agios Reports Favorable Phase II PK Deficiency Study Data
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 8:56AM CDT
Agios Pharmaceuticals (AGIO) reported encouraging initial data from an ongoing phase II DRIVE-PK study on pyruvate kinase deficiency candidate AG-348.
PFE: 37.31 (+0.42), RTRX: 18.17 (+0.24), AGIO: 45.69 (+0.46), BMY: 76.19 (+1.38)
Glaxo/J&J Sirukumab Positive in Rheumatoid Arthritis Study
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 10:01AM CDT
GlaxoSmithKline (GSK) and Johnson & Johnson's Janssen Biologics announced encouraging new phase III study data on rheumatoid arthritis candidate, sirukumab.
JNJ: 125.40 (+0.17), RTRX: 18.17 (+0.24), GSK: 45.25 (+0.18), BMY: 76.19 (+1.38)
The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
MACK: 5.82 (+0.02), BIIB: 301.83 (+11.90), IDRA: 1.67 (-0.05), RTRX: 18.17 (+0.24), ACOR: 25.13 (-0.15)
Orexigen Stock Gains More than 50% on Markman Hearing
Arpita Dutt - Zacks Investment Research - Thu Jun 09, 7:58AM CDT
Orexigen's (OREX) shares shot up on a favorable Markman hearing in the Contrave patent infringement lawsuit.
OREX: 3.38 (+0.03), RTRX: 18.17 (+0.24), VVUS: 1.05 (-0.02), ARNA: 1.68 (+0.01)
